Kangpu Biopharmaceuticals

Apr 28, 2025

Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE

Feb 25, 2025

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma

Sep 20, 2024

Kangpu Completed Bridging Clinical Study of KPG-818 in China

Jun 10, 2024

Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024

Jun 05, 2024

FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC

Feb 20, 2024

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

Nov 17, 2020

Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus

Jun 17, 2020

Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting